339
Views
14
CrossRef citations to date
0
Altmetric
Cisplatin Ovarian Damage and Erythropoietin

Could erythropoietin reduce the ovarian damage of cisplatin in female rats?

, , , , , & show all
Pages 309-313 | Received 15 Feb 2017, Accepted 16 Sep 2017, Published online: 30 Oct 2017

References

  • Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123–31.
  • Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222–9.
  • Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409–13.
  • Mori S, Sawada T, Okada T, et al. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 2008;143:556–65.
  • Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006;21:330–6.
  • Rjiba-Touati K, Boussema IA, Belarbia A, et al. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol 2011;30:510–17.
  • Maggioni D, Nicolini G, Chiorazzi A, et al. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. J Neurosci Res 2010;88:3171–9.
  • Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM. Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol 2013;65:197–203.
  • Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, et al. Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 2013;7:383–9.
  • Pezeshki Z, Nematbakhsh M, Mazaheri S, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012;2012:890310.
  • Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 1999;140:5789–96.
  • Osman P. Rate and course of atresia during follicular development in the adult cyclic rat. J Reprod Fertil 1985;73:261–70.
  • Guven S, Muci E, Unsal MA, et al. The effects of carbon dioxide pneumoperitoneum on ovarian blood flow, oxidative stress markers, and morphology during laparoscopy: a rabbit model. Fertil Steril 2010;93:1327–32.
  • Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res 2006;15:332–9.
  • Bakan V, Ciralik H, Tolun FI, et al. Protective effect of erythropoietin on torsion/detorsion injury in rat model. J Pediatr Surg 2009;44:1988–94.
  • Yasuda Y, Masuda S, Chikuma M, et al. Estrogen dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381–7.
  • Ergun Y, Koc A, Dolapcioglu K, et al. The protective effect of erythropoietin and dimethylsulfoxide on ischemia-reperfusion injury in rat ovary. Eur J Obstet Gynecol Reprod Biol 2010;152:186–90.
  • Karaca M, Odabasoglu F, Kumtepe Y, et al. Protective effects of erythropoietin on ischemia/reperfusion injury of rat ovary. Eur J Obstet Gynecol Reprod Biol 2009;144:157–62.
  • Solaroglu A, Kaptanoglu E, Dede S, et al. Erythropoietin prevents ischemia reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 2003;19:19–22.
  • Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.
  • van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065–71.
  • Yeh J, Kim B, Liang YJ, Peresie J. Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun 2006;348:337.
  • Erbaş O, Akman L, Yavaşoğlu A, et al. Oxytocin improves follicular reserve in a cisplatin-induced gonadotoxicity model in rats. Biomed Res Int 2014;2014:703691.
  • Yucebilgin MS, Terek MC, Ozsaran A, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004;44:6–9.
  • Taskin MI, Yay A, Adali E, et al. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol 2015;31:272–7.
  • Li X, Yang S, Lv X, et al. The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats. J Gynecol Oncol 2013;24:177–85.
  • Tan SJ, Yeh YC, Shang WJ, et al. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol 2010;149:182–5.
  • Lemos CN, Reis FM, Pena GN, et al. Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod Biol Endocrinol 2010;8:51.
  • Kaya C, Turgut H, Cengiz H, et al. The effect of tubal sterilization with the Pomeroy technique and bipolar electrocauterization on the ovarian reserve and serum anti-Müllerian hormone levels in a rat model. Eur J Obstet Gynecol Reprod Biol 2015;185:108–13.
  • Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34:1522–34.
  • Akdemir A, Sahin C, Erbas O, et al. Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary? Arch Gynecol Obstet 2015;292:445–50.
  • Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008;85:194–213.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.